PALVELLA THERAPEUTICS INC (PVLA)
Health Care · Rare disease therapeutics · NASDAQ
A clinical-stage biopharmaceutical company developing proprietary therapeutics for rare skin diseases and vascular malformations following the merger of Pieris Pharmaceuticals and Legacy Palvella.
What PALVELLA THERAPEUTICS INC does
Palvella Therapeutics (formerly Pieris Pharmaceuticals) is a biopharmaceutical company focused on developing proprietary drug candidates for rare skin diseases and vascular malformations. The company's current pipeline includes QTORIN rapamycin and QTORIN pitavastatin formulations, along with research-stage opportunities. Palvella was formed through a December 2024 merger between Pieris Pharmaceuticals and Legacy Palvella Therapeutics, combining their therapeutic platforms and capabilities.
Themes: ["Rare skin diseases","Vascular malformations","Clinical-stage therapeutics"]
Fundamentals
- Price$151.04 as of 2026-07-09 close
- Market cap$2.2B as of 2026-07-10
- 1-year return+485.4% as of 2026-07-09 close
- Net margin-39.7% as of 2026-07-10
- ROE-56.9% as of 2026-07-10
- Debt / equity0.09 as of 2026-07-10
- Revenue growth (YoY)-97.2% as of 2026-07-10
- Revenue CAGR (3y)+13.4% SEC XBRL
- Beta-0.21 as of 2026-07-10
Key risks (from latest filing)
["Clinical trial risk: ability of clinical trials to demonstrate safety and efficacy of product candidates is uncertain and required to advance pipeline","Regulatory and policy uncertainty: evolving regulatory environment and recent shifts in U.S. administration and government policy create uncertainty","Dependence on third parties: reliance on contract manufacturers and contract research organizations for drug development and manufacturing"]
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.